ClearPoint Neuro (NASDAQ:CLPT) vs. Inovio Pharmaceuticals (NASDAQ:INO) Head to Head Review

ClearPoint Neuro (NASDAQ:CLPTGet Rating) and Inovio Pharmaceuticals (NASDAQ:INOGet Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Volatility & Risk

ClearPoint Neuro has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Insider and Institutional Ownership

25.8% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 36.3% of Inovio Pharmaceuticals shares are held by institutional investors. 6.5% of ClearPoint Neuro shares are held by company insiders. Comparatively, 3.3% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ClearPoint Neuro and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ClearPoint Neuro -88.41% -31.18% -20.52%
Inovio Pharmaceuticals -17,104.84% -62.49% -53.30%

Valuation and Earnings

This table compares ClearPoint Neuro and Inovio Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ClearPoint Neuro $16.30 million 12.46 -$14.41 million ($0.67) -12.79
Inovio Pharmaceuticals $1.77 million 342.07 -$303.66 million ($1.45) -1.88

ClearPoint Neuro has higher revenue and earnings than Inovio Pharmaceuticals. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for ClearPoint Neuro and Inovio Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ClearPoint Neuro 0 0 1 0 3.00
Inovio Pharmaceuticals 0 5 1 0 2.17

ClearPoint Neuro presently has a consensus price target of $15.00, suggesting a potential upside of 75.03%. Inovio Pharmaceuticals has a consensus price target of $12.40, suggesting a potential upside of 354.21%. Given Inovio Pharmaceuticals’ higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than ClearPoint Neuro.

Summary

ClearPoint Neuro beats Inovio Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

ClearPoint Neuro Company Profile (Get Rating)

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Inovio Pharmaceuticals Company Profile (Get Rating)

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.